Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Baxalta Playing Hard to Get as Shire Sweetens Deal

Illinois-based Baxalta (BXLT) is still playing hard to get, as Dublin-based Shire (SHPGY) sweetened its deal to acquire the company. In July, Shire made a bid for Baxalta, which wasn’t accepted. In early August, Shire went public with the offer in hopes of pressuring the Baxalta board and shareholders to consider the deal. Baxalta had […]

Read More »

Adamas says lead drug meets late-stage study goals

Drugmaker Adamas Pharmaceuticals Inc’s experimental treatment to reduce the side effect of a commonly prescribed Parkinson’s drug met the main goal of a late-stage study, sending its shares up as much as 58.5 percent. Shares of the company jumped to $26.72 in Wednesday morning trade. The company was trading at similar levels in June when […]

Read More »

Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment

Strategic agreement with Kedrion for clinical development and marketing Plans to file a BLA with the FDA in mid-2016   NESS ZIONA, Israel–(BUSINESS WIRE)–Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, reports that the pivotal Phase 2/3 clinical trial with the Company’s human rabies immune globulin (IgG or KamRAB™ or […]

Read More »

Sanofi submits new diabetes drug application to U.S. regulator

French drugmaker Sanofi said on Wednesday it had submitted an application to the U.S. Food and Drug Administration (FDA) for a single daily insulin injection to treat adults with type 2 diabetes.   Sanofi said it had requested a six-month review of its new drug application by the FDA, rather than the standard 10 months. […]

Read More »

AstraZeneca gets U.S. approval for gout drug Zurampic

U.S. health regulators on Tuesday approved AstraZeneca’s drug Zurampic to treat a condition associated with gout to be used in combination with another type of drug that reduces production of uric acid in the body. Zurampic, known chemically as lesinurad, works by helping the kidneys to excrete uric acid. Gout is a painful form of […]

Read More »

Celgene settles U.S. patent litigation for top seller Revlimid

Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire. The company said it would provide India-based Natco Pharma Ltd and its U.S. partner, Arrow International Limited, a unit of Allergan Plc, […]

Read More »

Amgen Acquires MediGene AG Spin-off

December 22, 2015 By Mark Terry, BioSpace.com Breaking News Staff   Munich, Germany-based Medigene AG (MDGEF.PK) announced yesterday that it had sold its spinoff company, Catherex, Inc., to Amgen (AMGN). Medigene, as primary Catherex shareholder, will receive about 40 percent of the payments from Amgen. Catherex shareholders will receive an upfront payment of $10.5 million […]

Read More »

Clinton announces plan to battle Alzheimer’s

Democratic presidential candidate Hillary Clinton on Tuesday announced a slate of proposals to battle Alzheimer’s disease and seek a cure by 2025, including an increase in funding for research on the disease and related disorders.   Clinton called for a decade-long investment of $2 billion per year for research, which her campaign called a fourfold […]

Read More »

TPG invests $75 million into life sciences service firm: sources

The growth equity arm of buyout firm TPG Capital LP has invested $75 million in life sciences services company Precision for Medicine, according to people familiar with the matter, the latest in a string of TPG investments in the healthcare sector. The sources asked not to be identified ahead of an announcement of the investment […]

Read More »

PSivida Corp says experimental eye therapy meets study goal

Drugmaker pSivida Corp said its lead experimental therapy prevented inflammation in the back of patients’ eyes in a late-stage study. The company’s shares were up 27 percent at $4.70 in premarket trading on Tuesday. The drugmaker said only 18.4 percent of the patients given the treatment Medidur had the condition, posterior uveitis, return, compared with […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom